Conquer Cancer Announces Recipients of the 2019 Breakthrough Summit Abstract and Merit Awards

Conquer Cancer Merit AwardConquer Cancer®, the ASCO Foundation is proud to announce the recipients of its 2019 Breakthrough Summit Merit and Abstract Awards. These awards recognize oncology fellows, junior faculty, and trainees for their valuable research in clinical cancer treatment and technology innovations in cancer care. Awardees will present their research at the inaugural ASCO Breakthrough: A Global Summit for Oncology meeting taking place on October 11-13, 2019, in Bangkok, Thailand. 

Abstract Awards support the first authors of the 50 highest-rated abstracts selected for presentation at the ASCO Breakthrough Summit. The awards are supported by Conquer Cancer’s Mission Endowment. See the complete list of 2019 Breakthrough Summit Abstract Award recipients. 

Merit Awards recognize the quality and scientific merit of research submitted by oncology fellows and trainees to an ASCO meeting.

The 2019 recipients for the ASCO Breakthrough Summit are: 
Kin Wai (Tony) Hung, MD, MBA
Olive View Medical Center, University of California

Karen Levy, MD
Stanford University

Hongnan Mo, MD
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Reza Moghareabed, MD
Isfahan University of Medical Sciences

Ankur Sharma, PhD
Genome Institute of SIngapore

Polina Shilo, MD
I. V. Davidovskiy Hospital

Vijay Kumar Srinivasalu, MBBS, MD
Mazumdar Shaw Medical Center

Akiko Tateishi, MD
National Cancer Center Hospital

Victoria Teoh, MBBS, MRM, MFSTEd, FRCS
The Royal Marsden NHS Foundation Trust

Liang Wen, MD, PhD
First Affiliated Hospital of Zhejiang University School of Medicine

Xiufeng Wu, MD, PhD
Fujian Provincial Cancer Hospital

Yudi Xiong, MD
Zhongnan Hospital of Wuhan University

Supporters: 
The 2019 Conquer Cancer Foundation of ASCO Merit Awards are supported by Anonymous, Agios Pharmaceuticals, Inc., ASCO Employees, Association of Northern California Oncologists, AstraZeneca, Friends and Family of Dr. and Mrs. Ronald Beller, The Berry Family, Dr. and Mrs. Douglas W. Blayney, Breast Cancer Research Foundation®, Bristol-Myers Squibb, Jonathan K. and Cora Y. Cho Charitable Fund, Eisai Inc., Estate of Darla C. Ellis, Epiphany Partners Inc., G1 Therapeutics, GlaxoSmithKline Oncology, Dr. Arti Hurria and Dr. Hyman B. Muss, Ipsen Biopharmaceuticals Inc., Michael Kelley, MD & Elise Hoffman, PharmD, Kidney Cancer Association, Lilly, Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company, Merck & Co., Inc., Friends and Family of Dr. James B. Nachman, Northern New England Clinical Oncology Society, Dr. Kathleen Pritchard Medicine Professional Corporation, Sarah Cannon Research Institute, Frances A. Shepherd, MD, FASCO, Stephen A. Sherwin, MD, Drs. Rachna and Puneet Shroff, Nizar M. Tannir, MD, TESARO, a GSK Company, and Dr. Michael and Deborah Troner 

This listing is current as of October 7, 2019.